Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina
WOBURN, Mass. and HARPENDEN, United Kingdom, June 17, 2024 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that U.K.-based Rothamsted Research Limited (“Rothamsted”) has granted to the Company an exclusive global, commercial license to advanced technology for producing sustainable omega-3 products in Camelina sativa (“Camelina”). Yield10 is executing a plan to use engineered Camelina to commercially produce omega-3 oil and meal products targeting the aquafeed, petfood, and nutritional markets for omega-3 fatty acids. In consideration for the commercial license, Yield10 is expected to pay certain license fees, future milestone payments, and royalties based on commercialization of Rothamsted’s omega-3 technology.
Related news for (YTEN)
- Yield10 Bioscience Announces Second Quarter 2024 Financial Results
- Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
- Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label
- Yield10 Bioscience Announces First Quarter 2024 Financial Results